Barbara Thorne

Barbara Thorne has over 25 years of experience in process development of recombinant proteins, viral vectors, and vaccines, and has worked in small biotech, large pharma, and contract manufacturing organizations (CMO). She has most recently been Executive Director of Product Development at Celladon Corporation, a late-stage clinical biotechnology company developing MYDICAR (AAV1/SERCA2a) to treat heart failure.

She directed process and analytical development for this large-market indication, adeno-associated viral vector (AAV) gene therapy product in preparation for phase 3 and commercialization and was the scientific lead in a highly effective interdisciplinary development team working in a virtual model. Previously Dr. Thorne was director of Process Development at Targeted Genetics Corporation (TGC), Seattle WA where she was responsible for developing manufacturing processes for AAV and adenoviral vectors. She has also held various scientific and process development roles at Bristol Myers Squibb, and consulted for biotechnology and contract manufacturing organizations. She received her PhD in molecular biology from the University of Oregon.